Al-Dhaheri Mariam H, Rowan Brian G
Department of Biochemistry and Cancer Biology, Health Science Campus, University of Toledo, Ohio 43614, USA.
Mol Endocrinol. 2007 Feb;21(2):439-56. doi: 10.1210/me.2006-0059. Epub 2006 Oct 26.
Inhibition of protein kinase A (PKA) promotes estrogen-dependent growth of MCF7 breast cancer cells, although the mechanisms by which PKA regulates estrogen receptor (ER) function remain unclear. In this study elevation of cAMP by forskolin/3-isobutyl-1-methylxanthine (F/I) suppressed estradiol-dependent MCF7 and T47D breast cancer cell growth but not tamoxifen-resistant MCF7-LCC2 cells. Although F/I induced ligand independent activation of ERalpha, F/I also decreased estradiol-dependent reporter gene transcription. Overexpression of PKA or PKA inhibitor (PKI) demonstrated that F/I effects on repression of estradiol action occurred through the PKA pathway. 8CPT-2Me-cAMP, a selective inducer of non-PKA signaling, did not alter ER-dependent transcription. In contrast to F/I effects on reporter genes, F/I exhibited gene-specific effects on endogenous, ER-regulated genes. F/I enhanced estradiol induction of pS2 and cMyc but repressed estradiol induction of cyclin D1 mRNA and protein in MCF7 cells. To explore likely mechanisms by which F/I regulated ER, experiments examined estradiol binding, Hsp90 interaction, promoter recruitment, and ERalpha phosphorylation. F/I decreased estradiol binding and increased Hsp90 association with ERalpha. Chromatin immunoprecipitation revealed that F/I recruited ERalpha to both pS2 and cMyc promoters at earlier times than estradiol, and F/I shifted estradiol recruitment of ERalpha to earlier time points. F/I induced a unique ERalpha phosphorylation profile (increase in serine 305 and decrease in serine 118 phosphorylation) that was distinct from estradiol and estradiol + F/I. Taken together, F/I signaling through PKA selectively regulates estradiol-dependent genes in breast cancer, which is associated with reduced ligand binding and changes in promoter interaction and ERalpha phosphorylation.
抑制蛋白激酶A(PKA)可促进MCF7乳腺癌细胞的雌激素依赖性生长,尽管PKA调节雌激素受体(ER)功能的机制尚不清楚。在本研究中,福斯高林/3-异丁基-1-甲基黄嘌呤(F/I)提高cAMP水平可抑制雌二醇依赖性的MCF7和T47D乳腺癌细胞生长,但对他莫昔芬耐药的MCF7-LCC2细胞无效。虽然F/I诱导了ERα的非配体依赖性激活,但F/I也降低了雌二醇依赖性报告基因的转录。PKA或PKA抑制剂(PKI)的过表达表明,F/I对雌二醇作用的抑制效应是通过PKA途径发生的。8-对氯苯硫基-2'-O-甲基腺苷-3',5'-环磷酸酯(8CPT-2Me-cAMP),一种非PKA信号的选择性诱导剂,并未改变ER依赖性转录。与F/I对报告基因的影响相反,F/I对内源性ER调节基因表现出基因特异性影响。F/I增强了pS2和cMyc的雌二醇诱导,但抑制了MCF7细胞中细胞周期蛋白D1 mRNA和蛋白的雌二醇诱导。为了探究F/I调节ER的可能机制,实验检测了雌二醇结合、热休克蛋白90(Hsp90)相互作用、启动子募集和ERα磷酸化。F/I降低了雌二醇结合,并增加了Hsp90与ERα的结合。染色质免疫沉淀显示,F/I比雌二醇更早地将ERα募集到pS2和cMyc启动子上,并且F/I将ERα的雌二醇募集转移到更早的时间点。F/I诱导了一种独特的ERα磷酸化模式(丝氨酸305磷酸化增加,丝氨酸118磷酸化减少),这与雌二醇以及雌二醇+F/I不同。综上所述,通过PKA的F/I信号选择性调节乳腺癌中的雌二醇依赖性基因,这与配体结合减少以及启动子相互作用和ERα磷酸化变化有关。